Yasodha Natkunam, M.D., Ph.D
Academic Appointments
- Associate Professor - Med Center Line, Pathology
- Member, Cancer Center
Contact Information
-
Clinical Offices
Department of Pathology 300 Pasteur Dr L235 MC 5324 Stanford, CA 94305 Tel Work (650) 725-9354 Fax (650) 725-7409Practices at Stanford Hospital and Clinics and Lucile Packard Children's Hospital
- Academic Offices
Personal Information Email Tel (650) 725-9354Not for medical emergencies or patient use
Professional Snapshot
Clinical Focus
- Hematopathology
- Pathology and Laboratory Medicine
- Anatomic/Clinical Pathology
Administrative Appointments
- Director of Hematopathology, Stanford (2009 - present)
- Associate Chair for Faculty Development and Diversity, Stanford (2009 - present)
Professional Education
| Residency: | SUMC - Graduate Medical Education, CA (2000) |
| Board Certification: | Anatomic Pathology, American Board of Pathology (1998) |
| Internship: | Stanford University School of Medicine, CA (1996) |
| Medical Education: | Mt. Sinai School of Medicine, NY (1995) |
| MD/PhD: | Mount Sinai, NY, Molecular Biology (1995) |
Postdoctoral Advisees
Graduate & Fellowship Program Affiliations
Community & International Work
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information
| Consulting: | Cytograft Tissue Engineering, Inc. |
Scientific Focus
Current Research Interests
My laboratory studies the tissue expression pattern of proteins that are of potential interest for the diagnosis, prognostic stratification and therapy of patients with lymphoma and leukemia. We are currently investigating prognostic markers in diffuse large B-cell lymphoma such that risk groups can be better defined. We are also interested in the immunodiagnostic and molecular characterization of rare and aggressive hematopoietic tumors such as Natural Killer/T-cell lymphomas, histiocytic malignancies and childhood lymphomas.
Clinical Trials
- Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia Recruiting
- Phase II study of Atorvastatin safety and antitumor effects in non-Hodgkin's Lymphoma Recruiting
- Phase I Intratumoral Dendritic Cell Immunotherapy in Thermally Ablated Liver Metastases Terminated
- Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer Completed
Publications
- CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. Hum Pathol. 2010; (2): 271-80
- Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. Mod Pathol. 2010
- PD-1 expression in T-cell lymphomas and reactive lymphoid entities: potential overlap in staining patterns between lymphoma and viral lymphadenitis. Am J Surg Pathol. 2010; (2): 178-89
- Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). Br J Haematol. 2010; (2): 235-44
- The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities. Am J Clin Pathol. 2009; (2): 264-78
Help